Methylphenidate transdermal system (US brand name Daytrana®) is a central nervous system stimulant. Here is basic information about this medication.
FDA-approved indications
Treatment of attention deficit hyperactivity disorder (ADHD) in children (6-12 years) and adolescents (13-17 years)
Dosage
Initial: 10 mg
Dosage should be titrated to effect. Dose titration, final dosage, and wear time should be individualized according to the needs and response of the patient.
Should be applied to the hip area (using alternating sites) 2 hours before an effect is needed and removed 9 hours after application. May be removed earlier if a shorter duration of effect is desired or late day side effects appear.
Dosage forms and strengths
Extended-release transdermal patch (Daytrana®): 10 mg/9 hr, 15 mg/9 hr, 20 mg/9 hr, and 30 mg/9 hr
Please refer to Prescribing Information (see link below) for complete discussion of dosage, administration, warnings and precautions, contraindications, etc.
Related Pages
Methylphenidate preparations
Should we prescribe dexmethylphenidate (Focalin) rather than methylphenidate (Ritalin)?
Should we combine methylphenidate and guanfacine?
Eight tips for reducing the risk of abuse/diversion of stimulants
Does lisdexamfetamine really have lower abuse potential?
Triple-bead preparation of mixed amphetamine salts (Mydayis®)
References
Methylphenidate transdermal system (Daytrana®) Prescribing Information
Copyright 2017, Rajnish Mago, MD. All rights reserved. May not be reproduced in any form without express written permission.
Disclaimer: The content on this website is provided as general education for medical professionals. It is not intended or recommended for patients or other laypersons, or as a substitute for medical advice, diagnosis, or treatment. Patients must always consult a qualified health care professional regarding their diagnosis and treatment. Healthcare professionals should always check this website for the most recently updated information.
Leave a Reply: